It was a delight to catch up with our Expert Faculty Member, Dr Gil Y Melmed (Cedars-Sinai Medical Center, Los Angeles, CA, US), to discuss the recent phase 2 and 3 analyses of herpes zoster infection in patients with ulcerative colitis receiving tofacitinib.
His abstract entitled ‘Herpes Zoster Infection in Patients with Ulcerative Colitis Receiving tofacitinib results from the Phase 2 and Phase 3 Clinical Programs’ (Fr5340) was presented at DDW, 21-23 May 2021.
- What has the tofacitinib UC clinical trial program taught us about the herpes zoster incidence during the induction and maintenance treatment of ulcerative colitis with tofacitinb? (0:17)
- Could you tell us a little about the analysis you presented at the Digestive Disease Week® (DDW) meeting, and its findings? (1:19)
- Which patients have the highest risk of herpes zoster? (3:19)
- What are the limitations of this analysis and what future studies are planned? (4:35)
Disclosures: Gil Y Melmed has consulted for AbbVie, Arena Pharmaceuticals, Boehringer-Ingelheim, Bristol-Meyers Squibb/Celgene, Entasis, Janssen, Medtronic, Pfizer, Samsung Bioepis, Shionogi, Takeda, Techlab, and has received research funding from Pfizer for an unrelated investigator-initiated study.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Victoria Jones.
Filmed as a highlight of DDW 2021 (Virtual).
Share this Video
Related Videos In Inflammatory Bowel Disease
Eamonn Quigley, DDW 2021: Biotherapeutic Blautia Hydrogentrophica in IBS
It was a pleasure to speak with Prof. Eamonn Quigley (Houston Methodist Hospital, Houston, TX, USA) about the phase 2 study of the single-strain live biotherapeutic, Blautia hydrogentrophica (Blautix), currently under investigation in irritable bowel syndrome (IBS). His abstract entitled ‘A Phase 2 Study of Live Biotherapeutic Blautix in Irritable Bowel Syndrome (IBS) Patients with […]
Stefan Schreiber, DDW 2021: Phase 2b/3 SELECTION and Long Term Extension Study Results
It was a pleasure to meet with Prof. Stefan Schreiber (Department of Internal Medicine, University Hospital Schleswig-Holstein, Institute for Clinical Molecular Biology, Kiel, Germany) to discuss the results from the Phase 2b/3 SELECTION and Phase 3 SELECTION long term extension study, investigating filgotinib for the treatment of ulcerative colitis. The abstract entitled ‘133: SAFETY ANALYSIS […]
Stefan Schreiber, DDW 2021: True North Study Results
It was a pleasure to meet with Prof. Stefan Schreiber (Department of Internal Medicine, University Hospital Schleswig-Holstein, Institute for Clinical Molecular Biology, Kiel, Germany) to discuss the results from the maintenance phase of the True North study, investigating corticosteroid free remission in patients with ulcerative colitis treated with ozanimod. The abstract entitled ‘142: CORTICOSTEROID-FREE REMISSION […]
Journal articles and more to your inbox
Get the latest clinical insights from touchIMMUNOLOGYSign me up!